Waksal's Kadmon acquires Three Rivers
This article was originally published in Scrip
Executive Summary
Kadmon Pharmaceuticals, led by former ImClone CEO Dr Samuel Waksal, has acquired Three Rivers Pharmaceuticals, a privately held specialty pharma, for $100 million.